{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:22:06Z","timestamp":1791994926016,"version":"4.4.0"},"reference-count":154,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2006,2,1]],"date-time":"2006-02-01T00:00:00Z","timestamp":1138752000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vascular Pharmacology"],"published-print":{"date-parts":[[2006,2]]},"DOI":"10.1016\/j.vph.2005.07.012","type":"journal-article","created":{"date-parts":[[2005,12,6]],"date-time":"2005-12-06T12:21:10Z","timestamp":1133871670000},"page":"75-89","source":"Crossref","is-referenced-by-count":72,"title":["Pharmacogenomics of cholesterol-lowering therapy"],"prefix":"10.1016","volume":"44","author":[{"given":"Gerd","family":"Schmitz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Langmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vph.2005.07.012_bib1","first-page":"1383","article-title":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)","volume":"344","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.vph.2005.07.012_bib2","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM199811053391902","article-title":"Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group","volume":"339","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.vph.2005.07.012_bib3","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1161\/01.CIR.102.1.21","article-title":"Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study","volume":"102","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.vph.2005.07.012_bib4","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/S0140-6736(00)04209-4","article-title":"Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study","volume":"357","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.vph.2005.07.012_bib5","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","article-title":"Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)","volume":"285","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.vph.2005.07.012_bib6","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.1001\/jama.288.23.2998","article-title":"Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT)","volume":"288","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.vph.2005.07.012_bib7","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial","volume":"360","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.vph.2005.07.012_bib8","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1161\/circ.106.25.3143","article-title":"Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report","volume":"106","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.vph.2005.07.012_bib9","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1161\/01.ATV.0000066133.32063.BB","article-title":"Change in alpha1 HDL concentration predicts progression in coronary artery stenosis","volume":"23","author":"Asztalos","year":"2003","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.vph.2005.07.012_bib10","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0021-9150(00)00726-7","article-title":"Statin-fibrate combinations in patients with combined hyperlipedemia","volume":"155","author":"Athyros","year":"2001","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.vph.2005.07.012_bib11","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/clc.4960240404","article-title":"Lessons learned from statin trials","volume":"24","author":"Auer","year":"2001","journal-title":"Clin. Cardiol."},{"key":"10.1016\/j.vph.2005.07.012_bib12","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1067\/mcp.2000.108507","article-title":"Plasma concentrations of active simvastatin acid are increased by gemfibrozil","volume":"68","author":"Backman","year":"2000","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.vph.2005.07.012_bib13","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1067\/mcp.2002.128469","article-title":"Gemfibrozil greatly increases plasma concentrations of cerivastatin","volume":"72","author":"Backman","year":"2002","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.vph.2005.07.012_bib14","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1002\/mus.20291","article-title":"Molecular clues into the pathogenesis of statin-mediated muscle toxicity","volume":"31","author":"Baker","year":"2005","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.vph.2005.07.012_bib15","first-page":"258","article-title":"Statin myopathies: pathophysiologic and clinical perspectives","volume":"24","author":"Baker","year":"2001","journal-title":"Clin. Invest. Med."},{"key":"10.1016\/j.vph.2005.07.012_bib16","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1016\/S0735-1097(00)00918-9","article-title":"Apolipoprotein E genotypes and response of plasma lipids and progression-regression of coronary atherosclerosis to lipid-lowering drug therapy","volume":"36","author":"Ballantyne","year":"2000","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.vph.2005.07.012_bib17","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1161\/01.ATV.0000015598.86369.04","article-title":"Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis","volume":"22","author":"Barbier","year":"2002","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.vph.2005.07.012_bib18","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1161\/01.ATV.0000013283.84306.1A","article-title":"Interleukin-6-174G>C polymorphism and risk of coronary heart disease in West of Scotland coronary prevention study (WOSCOPS)","volume":"22","author":"Basso","year":"2002","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.vph.2005.07.012_bib19","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/S0149-2918(01)80102-8","article-title":"Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies","volume":"23","author":"Bays","year":"2001","journal-title":"Clin. Ther."},{"key":"10.1016\/j.vph.2005.07.012_bib20","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S1086-5802(16)31104-4","article-title":"HMG-CoA reductase inhibitors: assessing differences in drug interactions and safety profiles","volume":"40","author":"Beaird","year":"2000","journal-title":"J. Am. Pharm. Assoc. (Wash.)"},{"key":"10.1016\/j.vph.2005.07.012_bib21","doi-asserted-by":"crossref","first-page":"III50","DOI":"10.1161\/01.CIR.0000131519.15067.1f","article-title":"Safety of statins: focus on clinical pharmacokinetics and drug interactions","volume":"109","author":"Bellosta","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.vph.2005.07.012_bib22","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1080\/07853890310014588","article-title":"Sitosterolemia: a gateway to new knowledge about cholesterol metabolism","volume":"35","author":"Berge","year":"2003","journal-title":"Ann. Med."},{"key":"10.1016\/j.vph.2005.07.012_bib23","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1097\/00041433-200112000-00004","article-title":"Lipid-lowering trials in diabetes","volume":"12","author":"Betteridge","year":"2001","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.vph.2005.07.012_bib24","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1161\/01.CIR.0000068311.40161.28","article-title":"Variants of toll-like receptor 4 modify the efficacy of statin therapy and the risk of cardiovascular events","volume":"107","author":"Boekholdt","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.vph.2005.07.012_bib25","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1038\/sj.bjp.0703920","article-title":"HMG-CoA reductase inhibitors and P-glycoprotein modulation","volume":"132","author":"Bogman","year":"2001","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.vph.2005.07.012_bib26","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S0002-9149(01)01677-0","article-title":"The platelet Pl(A2) and angiotensin-converting enzyme (ACE) D allele polymorphisms and the risk of recurrent events after acute myocardial infarction","volume":"88","author":"Bray","year":"2001","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.vph.2005.07.012_bib27","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1056\/NEJMoa011090","article-title":"Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease","volume":"345","author":"Brown","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.vph.2005.07.012_bib28","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1161\/01.ATV.19.2.187","article-title":"Systematic review on the risk and benefit of different cholesterol-lowering interventions","volume":"19","author":"Bucher","year":"1999","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.vph.2005.07.012_bib29","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/S0002-8703(03)00501-5","article-title":"The cholesteryl ester transfer protein Taq1B gene polymorphism predicts clinical benefit of statin therapy in patients with significant coronary artery disease","volume":"146","author":"Carlquist","year":"2003","journal-title":"Am. Heart J."},{"key":"10.1016\/j.vph.2005.07.012_bib30","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/0026-0495(93)90066-W","article-title":"The response to lovastatin treatment in patients with heterozygous familial hypercholesterolemia is modulated by apolipoprotein E polymorphism","volume":"42","author":"Carmena","year":"1993","journal-title":"Metabolism"},{"key":"10.1016\/j.vph.2005.07.012_bib31","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1185\/030079904125004402","article-title":"Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid\u2014a position paper developed by the European Consensus Panel on HDL-C","volume":"20","author":"Chapman","year":"2004","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.vph.2005.07.012_bib32","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1001\/jama.291.23.2821","article-title":"Pharmacogenetic study of statin therapy and cholesterol reduction","volume":"291","author":"Chasman","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.vph.2005.07.012_bib33","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/00008571-200401000-00007","article-title":"Effects of PPARalpha, gamma and delta haplotypes on plasma levels of lipids, severity and progression of coronary atherosclerosis and response to statin therapy in the lipoprotein coronary atherosclerosis study","volume":"14","author":"Chen","year":"2004","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.vph.2005.07.012_bib34","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s000110050622","article-title":"Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation","volume":"49","author":"Chinetti","year":"2000","journal-title":"Inflamm. Res."},{"key":"10.1016\/j.vph.2005.07.012_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0163-7258(98)00016-3","article-title":"Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: are the statins mechanistically similar?","volume":"80","author":"Christians","year":"1998","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.vph.2005.07.012_bib36","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0163-7258(99)00045-5","article-title":"New insights into the pharmacodynamic and pharmacokinetic properties of statins","volume":"84","author":"Corsini","year":"1999","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.vph.2005.07.012_bib37","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.pcad.2004.04.007","article-title":"Comparative effects of lipid-lowering therapies","volume":"47","author":"Davidson","year":"2004","journal-title":"Prog. Cardiovasc. Dis."},{"key":"10.1016\/j.vph.2005.07.012_bib38","doi-asserted-by":"crossref","first-page":"33586","DOI":"10.1074\/jbc.M405817200","article-title":"Niemann-Pick C1 Like 1 (NPC1L1) is the intestinal phytosterol and cholesterol transporter and a key modulator of whole-body cholesterol homeostasis","volume":"279","author":"Davis","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.vph.2005.07.012_bib39","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.jacc.2003.08.056","volume":"43","author":"de Grooth","year":"2004","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.vph.2005.07.012_bib42","doi-asserted-by":"crossref","first-page":"36703","DOI":"10.1074\/jbc.M004045200","article-title":"Induction of IkappaBalpha expression as a mechanism contributing to the anti-inflammatory activities of peroxisome proliferator-activated receptor-alpha activators","volume":"275","author":"Delerive","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.vph.2005.07.012_bib40","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1161\/01.ATV.18.2.265","article-title":"\u2212455G\/A polymorphism of the beta-fibrinogen gene is associated with the progression of coronary atherosclerosis in symptomatic men: proposed role for an acute-phase reaction pattern of fibrinogen. REGRESS group","volume":"18","author":"de Maat","year":"1998","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.vph.2005.07.012_bib41","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S0002-9149(98)01073-X","article-title":"Effect of the stromelysin-1 promoter on efficacy of pravastatin in coronary atherosclerosis and restenosis","volume":"83","author":"de Maat","year":"1999","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.vph.2005.07.012_bib43","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1023\/A:1024212026578","article-title":"Genetic polymorphisms in emerging cardiovascular risk factors and response to statin therapy","volume":"17","author":"Dornbrook-Lavender","year":"2003","journal-title":"Cardiovasc. Drugs Ther."},{"key":"10.1016\/j.vph.2005.07.012_bib44","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1001\/jama.279.20.1615","article-title":"Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS\/TexCAPS. Air Force\/Texas Coronary Atherosclerosis Prevention Study","volume":"279","author":"Downs","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.vph.2005.07.012_bib45","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1146\/annurev.biochem.68.1.157","article-title":"Sterols and isoprenoids: signaling molecules derived from the cholesterol biosynthetic pathway","volume":"68","author":"Edwards","year":"1999","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.vph.2005.07.012_bib46","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1007\/s001090000154","article-title":"A prospective study of genetic markers of susceptibility to infection and inflammation, and the severity, progression, and regression of coronary atherosclerosis and its response to therapy","volume":"78","author":"Elghannam","year":"2000","journal-title":"J. Mol. Med."},{"key":"10.1016\/j.vph.2005.07.012_bib47","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/0925-4439(95)00028-3","article-title":"Biochemical, physiological and medical aspects of ubiquinone function","volume":"1271","author":"Ernster","year":"1995","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.vph.2005.07.012_bib48","doi-asserted-by":"crossref","first-page":"197","DOI":"10.2165\/00002018-200023030-00003","article-title":"Comparative tolerability of the HMG-CoA reductase inhibitors","volume":"23","author":"Farmer","year":"2000","journal-title":"Drug Saf."},{"key":"10.1016\/j.vph.2005.07.012_bib49","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1006\/taap.1997.8174","article-title":"HMG CoA reductase inhibitor-induced myotoxicity: pravastatin and lovastatin inhibit the geranylgeranylation of low-molecular-weight proteins in neonatal rat muscle cell culture","volume":"145","author":"Flint","year":"1997","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.vph.2005.07.012_bib50","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1016\/j.ehj.2003.07.001","article-title":"A polymorphism of the cholesteryl ester transfer protein gene predicts cardiovascular events in non-smokers in the West of Scotland Coronary Prevention Study","volume":"24","author":"Freeman","year":"2003","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.vph.2005.07.012_bib51","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1056\/NEJM198711123172001","article-title":"Helsinki heart study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease","volume":"317","author":"Frick","year":"1987","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.vph.2005.07.012_bib52","doi-asserted-by":"crossref","first-page":"671","DOI":"10.7326\/0003-4819-140-8-200404200-00034","article-title":"Ezetimibe and statin-associated myopathy","volume":"140","author":"Fux","year":"2004","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.vph.2005.07.012_bib53","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1046\/j.1365-2362.2002.00996.x","article-title":"Allelic polymorphism-491A\/T in apo E gene modulates the lipid-lowering response in combined hyperlipidemia treatment","volume":"32","author":"Garcia-Otin","year":"2002","journal-title":"Eur. J. Clin. Investig."},{"key":"10.1016\/j.vph.2005.07.012_bib54","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1161\/01.CIR.101.12.1366","article-title":"The apolipoprotein epsilon4 allele determines prognosis and the effect on prognosis of simvastatin in survivors of myocardial infarction: a substudy of the Scandinavian simvastatin survival study","volume":"101","author":"Gerdes","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.vph.2005.07.012_bib55","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1002\/j.1552-4604.1993.tb03948.x","article-title":"Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study","volume":"33","author":"Ghirlanda","year":"1993","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.vph.2005.07.012_bib56","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/S0002-9343(99)80185-5","article-title":"The prevalence of side effects with regular and sustained-release nicotinic acid","volume":"99","author":"Gibbons","year":"1995","journal-title":"Am. J. Med."},{"key":"10.1016\/j.vph.2005.07.012_bib57","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S0008-6363(00)00106-1","article-title":"HMG CoA reductase inhibition reduces sarcolemmal Na(+)\u2013K(+) pump density","volume":"47","author":"Gray","year":"2000","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.vph.2005.07.012_bib58","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.jacc.2004.07.001","article-title":"Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines","volume":"44","author":"Grundy","year":"2004","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.vph.2005.07.012_bib59","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1515\/CCLM.2000.103","article-title":"Association of the apolipoprotein B gene polymorphisms with cholesterol levels and response to fluvastatin in Brazilian individuals with high risk for coronary heart disease","volume":"38","author":"Guzman","year":"2000","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.vph.2005.07.012_bib60","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1542\/peds.91.5.915","article-title":"Clinical and biochemical phenotype in 11 patients with mevalonic aciduria","volume":"91","author":"Hoffmann","year":"1993","journal-title":"Pediatrics"},{"key":"10.1016\/j.vph.2005.07.012_bib61","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/00041433-199904000-00008","article-title":"Sterol regulatory element-binding proteins: activators of cholesterol and fatty acid biosynthesis","volume":"10","author":"Horton","year":"1999","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.vph.2005.07.012_bib62","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1097\/00008571-200112000-00005","article-title":"The genetic determinants of the CYP3A5 polymorphism","volume":"11","author":"Hustert","year":"2001","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.vph.2005.07.012_bib63","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1007\/s10038-004-0188-6","article-title":"A frameshift variant of CYP2C8 was identified in a patient who suffered from rhabdomyolysis after administration of cerivastatin","volume":"49","author":"Ishikawa","year":"2004","journal-title":"J. Hum. Genet."},{"key":"10.1016\/j.vph.2005.07.012_bib64","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1016\/S0149-2918(03)80281-3","article-title":"Pharmacology and therapeutics of ezetimibe (SCH 58235), a cholesterol-absorption inhibitor","volume":"25","author":"Jeu","year":"2003","journal-title":"Clin. Ther."},{"key":"10.1016\/j.vph.2005.07.012_bib65","doi-asserted-by":"crossref","first-page":"649","DOI":"10.3109\/07853899109148098","article-title":"Coenzyme Q10, alpha-tocopherol and free cholesterol in HDL and LDL fractions","volume":"23","author":"Johansen","year":"1991","journal-title":"Ann. Med."},{"key":"10.1016\/j.vph.2005.07.012_bib66","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.amjcard.2004.08.076","article-title":"Reporting rate of rhabdomyolysis with fenofibrate+statin versus gemfibrozil+any statin","volume":"95","author":"Jones","year":"2005","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.vph.2005.07.012_bib67","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1161\/01.CIR.94.8.1913","article-title":"The Asp9 Asn mutation in the lipoprotein lipase gene is associated with increased progression of coronary atherosclerosis. REGRESS Study Group, Interuniversity Cardiology Institute, Utrecht, The Netherlands. Regression Growth Evaluation Statin Study","volume":"94","author":"Jukema","year":"1996","journal-title":"Circulation"},{"key":"10.1016\/j.vph.2005.07.012_bib68","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1194\/jlr.M300278-JLR200","article-title":"ATP binding cassette transporter G5 and G8 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin","volume":"45","author":"Kajinami","year":"2004","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.vph.2005.07.012_bib69","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.amjcard.2003.08.078","article-title":"CYP3A4 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin in primary hypercholesterolemia","volume":"93","author":"Kajinami","year":"2004","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.vph.2005.07.012_bib70","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.atherosclerosis.2004.03.015","article-title":"Interactions between common genetic polymorphisms in ABCG5\/G8 and CYP7A1 on LDL-cholesterol-lowering response to atorvastatin","volume":"175","author":"Kajinami","year":"2004","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.vph.2005.07.012_bib71","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.amjcard.2004.01.014","article-title":"Polymorphisms in the multidrug resistance-1 (MDR1) gene influence the response to atorvastatin treatment in a gender-specific manner","volume":"93","author":"Kajinami","year":"2004","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.vph.2005.07.012_bib72","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.atherosclerosis.2004.09.004","article-title":"Pharmacogenetics of HMG-CoA reductase inhibitors: exploring the potential for genotype-based individualization of coronary heart disease management","volume":"177","author":"Kajinami","year":"2004","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.vph.2005.07.012_bib73","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.atherosclerosis.2004.08.034","article-title":"Gender-specific effects of estrogen receptor alpha gene haplotype on high-density lipoprotein cholesterol response to atorvastatin: interaction with apolipoprotein AI gene polymorphism","volume":"178","author":"Kajinami","year":"2005","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.vph.2005.07.012_bib74","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1016\/S0140-6736(04)16359-9","article-title":"The nicotinic acid receptor\u2014a new mechanism for an old drug","volume":"363","author":"Karpe","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.vph.2005.07.012_bib75","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S0009-9236(03)00121-8","article-title":"Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (\u2212)-3S,5R-fluvastatin and (+)-3R,5S-fluvastatin in healthy volunteers","volume":"74","author":"Kirchheiner","year":"2003","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.vph.2005.07.012_bib76","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1097\/01.fpc.0000114762.78957.a5","article-title":"Lipid-lowering response to statins is affected by CYP3A5 polymorphism","volume":"14","author":"Kivisto","year":"2004","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.vph.2005.07.012_bib77","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1056\/NEJM199908123410707","article-title":"Drug treatment of lipid disorders","volume":"341","author":"Knopp","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.vph.2005.07.012_bib78","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S0195-668X(02)00807-2","article-title":"Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia","volume":"24","author":"Knopp","year":"2003","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.vph.2005.07.012_bib79","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1074\/jbc.M406309200","article-title":"Aminopeptidase N (CD13) is a molecular target of the cholesterol absorption inhibitor Ezetimibe in the enterocyte brush border membrane","volume":"280","author":"Kramer","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.vph.2005.07.012_bib80","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1210\/jc.87.2.423","article-title":"Clinical review 141: lipids and atherosclerosis: lessons learned from randomized controlled trials of lipid lowering and other relevant studies","volume":"87","author":"Kreisberg","year":"2002","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.vph.2005.07.012_bib81","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1056\/NEJM199801083380203","article-title":"The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group","volume":"338","author":"Kuivenhoven","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.vph.2005.07.012_bib82","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1007\/s00109-002-0398-3","article-title":"Endothelial nitric oxide synthase genotype modulates the improvement of coronary blood flow by pravastatin: a placebo-controlled PET study","volume":"80","author":"Kunnas","year":"2002","journal-title":"J. Mol. Med."},{"key":"10.1016\/j.vph.2005.07.012_bib83","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1021\/js970100b","article-title":"The role of P-glycoprotein and canalicular multispecific organic anion transporter in the hepatobiliary excretion of drugs","volume":"87","author":"Kusuhara","year":"1998","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.vph.2005.07.012_bib84","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1067\/mcp.2001.115542","article-title":"Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate","volume":"69","author":"Kyrklund","year":"2001","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.vph.2005.07.012_bib85","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/S0009-9236(03)00052-3","article-title":"Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance","volume":"73","author":"Kyrklund","year":"2003","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.vph.2005.07.012_bib86","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S0021-9150(03)00094-7","article-title":"Apo A-I promoter polymorphism influences basal HDL-cholesterol and its response to pravastatin therapy","volume":"168","author":"Lahoz","year":"2003","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.vph.2005.07.012_bib87","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1001\/jama.282.24.2340","article-title":"Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials","volume":"282","author":"LaRosa","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.vph.2005.07.012_bib88","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1161\/01.CIR.0000130070.96758.7b","article-title":"The microsomal triglyceride transfer protein gene-493T variant lowers cholesterol but increases the risk of coronary heart disease","volume":"109","author":"Ledmyr","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.vph.2005.07.012_bib89","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1097\/00008571-200310000-00007","article-title":"Interleukin-1B genotype modulates the improvement of coronary artery reactivity by lipid-lowering therapy with pravastatin: a placebo-controlled positron emission tomography study in young healthy men","volume":"13","author":"Lehtimaki","year":"2003","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.vph.2005.07.012_bib90","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1038\/nm1102-1257","article-title":"Stabilization of atherosclerotic plaques: new mechanisms and clinical targets","volume":"8","author":"Libby","year":"2002","journal-title":"Nat. Med."},{"key":"10.1016\/j.vph.2005.07.012_bib91","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1212\/WNL.41.7.1159","article-title":"Cholesterol-lowering agent myopathy (CLAM)","volume":"41","author":"London","year":"1991","journal-title":"Neurology"},{"key":"10.1016\/j.vph.2005.07.012_bib92","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1161\/hh0901.090301","article-title":"Novel polymorphisms in promoter region of atp binding cassette transporter gene and plasma lipids, severity, progression, and regression of coronary atherosclerosis and response to therapy","volume":"88","author":"Lutucuta","year":"2001","journal-title":"Circ. Res."},{"key":"10.1016\/j.vph.2005.07.012_bib93","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0021-9150(01)00725-0","article-title":"Genetic polymorphisms: importance for response to HMG-CoA reductase inhibitors","volume":"163","author":"Maitland-van der Zee","year":"2002","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.vph.2005.07.012_bib94","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1097\/00008571-200304000-00006","article-title":"Adherence to and dosing of beta-hydroxy-beta-methylglutaryl coenzyme A reductase inhibitors in the general population differs according to apolipoprotein E-genotypes","volume":"13","author":"Maitland-van der Zee","year":"2003","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.vph.2005.07.012_bib95","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1007\/s11886-003-0109-x","article-title":"Niacin, lipids, and heart disease","volume":"5","author":"Malik","year":"2003","journal-title":"Curr. Cardiol. Rep."},{"key":"10.1016\/j.vph.2005.07.012_bib96","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1097\/00008571-200110000-00009","article-title":"Paraoxonase genotype modifies the effect of pravastatin on high-density lipoprotein cholesterol","volume":"11","author":"Malin","year":"2001","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.vph.2005.07.012_bib97","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0735-1097(99)00535-5","article-title":"Interactions between angiotensin-I converting enzyme insertion\/deletion polymorphism and response of plasma lipids and coronary atherosclerosis to treatment with fluvastatin: the Lipoprotein and Coronary Atherosclerosis Study","volume":"35","author":"Marian","year":"2000","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.vph.2005.07.012_bib98","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1161\/01.CIR.101.2.207","article-title":"Current perspectives on statins","volume":"101","author":"Maron","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.vph.2005.07.012_bib99","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1056\/NEJM199604043341403","article-title":"Recent trends in acute coronary heart disease-mortality, morbidity, medical care, and risk factors. The Minnesota Heart Survey Investigators","volume":"334","author":"McGovern","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.vph.2005.07.012_bib100","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1091\/mbc.11.8.2513","article-title":"Critical activities of Rac1 and Cdc42Hs in skeletal myogenesis: antagonistic effects of JNK and p38 pathways","volume":"11","author":"Meriane","year":"2000","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.vph.2005.07.012_bib101","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2165\/00003088-199834020-00003","article-title":"Clinical pharmacokinetics of fibric acid derivatives (fibrates)","volume":"34","author":"Miller","year":"1998","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.vph.2005.07.012_bib102","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S0140-6736(04)15739-5","article-title":"Selenoprotein synthesis and side-effects of statins","volume":"363","author":"Moosmann","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.vph.2005.07.012_bib103","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1067\/mcp.2001.120251","article-title":"Association of polymorphism in the cytochrome CYP2D6 and the efficacy and tolerability of simvastatin","volume":"70","author":"Mulder","year":"2001","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.vph.2005.07.012_bib104","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/S0022-3565(24)29609-9","article-title":"Human liver-specific organic anion transporter, LST-1, mediates uptake of pravastatin by human hepatocytes","volume":"297","author":"Nakai","year":"2001","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.vph.2005.07.012_bib105","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S0021-9150(96)06031-5","article-title":"A comparative study of the efficacy of simvastatin and gemfibrozil in combined hyperlipoproteinemia: prediction of response by baseline lipids, apo E genotype, lipoprotein(a) and insulin","volume":"129","author":"Nestel","year":"1997","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.vph.2005.07.012_bib106","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1097\/01.fpc.0000114750.08559.32","article-title":"High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1)","volume":"14","author":"Niemi","year":"2004","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.vph.2005.07.012_bib107","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/S0009-9236(03)00060-2","article-title":"Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics","volume":"73","author":"Nishizato","year":"2003","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.vph.2005.07.012_bib109","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/j.1365-2796.1991.tb00464.x","article-title":"Effect of apolipoprotein E polymorphism and XbaI polymorphism of apolipoprotein B on response to lovastatin treatment in familial and non-familial hypercholesterolaemia","volume":"230","author":"Ojala","year":"1991","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.vph.2005.07.012_bib108","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1161\/01.ATV.21.5.832","article-title":"Determinants of variable response to statin treatment in patients with refractory familial hypercholesterolemia","volume":"21","author":"O'Neill","year":"2001","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.vph.2005.07.012_bib111","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/0021-9150(94)05439-P","article-title":"Effect of apolipoprotein E and A-IV phenotypes on the low density lipoprotein response to HMG CoA reductase inhibitor therapy","volume":"113","author":"Ordovas","year":"1995","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.vph.2005.07.012_bib110","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1161\/01.ATV.20.5.1323","article-title":"Association of cholesteryl ester transfer protein-TaqIB polymorphism with variations in lipoprotein subclasses and coronary heart disease risk: the Framingham study","volume":"20","author":"Ordovas","year":"2000","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.vph.2005.07.012_bib112","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S1567-5688(02)00002-8","article-title":"Pharmacological interactions of statins","volume":"3","author":"Paoletti","year":"2002","journal-title":"Atheroscler. Suppl."},{"key":"10.1016\/j.vph.2005.07.012_bib113","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0021-9150(01)00410-5","article-title":"Apolipoprotein E genotype affects plasma lipid response to atorvastatin in a gender specific manner","volume":"158","author":"Pedro-Botet","year":"2001","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.vph.2005.07.012_bib114","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1093\/hmg\/ddg115","article-title":"Selenoprotein N: an endoplasmic reticulum glycoprotein with an early developmental expression pattern","volume":"12","author":"Petit","year":"2003","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.vph.2005.07.012_bib115","doi-asserted-by":"crossref","first-page":"581","DOI":"10.7326\/0003-4819-137-7-200210010-00009","article-title":"Statin-associated myopathy with normal creatine kinase levels","volume":"137","author":"Phillips","year":"2002","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.vph.2005.07.012_bib116","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1001\/jama.264.1.71","article-title":"Myopathy and rhabdomyolysis associated with lovastatin\u2013gemfibrozil combination therapy","volume":"264","author":"Pierce","year":"1990","journal-title":"JAMA"},{"key":"10.1016\/j.vph.2005.07.012_bib117","doi-asserted-by":"crossref","first-page":"32833","DOI":"10.1074\/jbc.273.49.32833","article-title":"Peroxisome proliferator-activated receptor alpha activation modulates cellular redox status, represses nuclear factor-kappaB signaling, and reduces inflammatory cytokine production in aging","volume":"273","author":"Poynter","year":"1998","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.vph.2005.07.012_bib118","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1172\/JCI0215387","article-title":"Human cholesterol 7alpha-hydroxylase (CYP7A1) deficiency has a hypercholesterolemic phenotype","volume":"110","author":"Pullinger","year":"2002","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.vph.2005.07.012_bib119","doi-asserted-by":"crossref","first-page":"42J","DOI":"10.1016\/S0002-9149(03)00615-5","article-title":"Regulation of reverse cholesterol transport and clinical implications","volume":"92","author":"Rader","year":"2003","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.vph.2005.07.012_bib120","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1097\/00041433-200312000-00005","article-title":"Cardiovascular disease with diabetes or the metabolic syndrome: should statins or fibrates be first line lipid therapy?","volume":"14","author":"Robins","year":"2003","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.vph.2005.07.012_bib121","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1001\/archinte.159.15.1793","article-title":"Clinical outcomes in statin treatment trials: a meta-analysis","volume":"159","author":"Ross","year":"1999","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.vph.2005.07.012_bib122","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1056\/NEJM199908053410604","article-title":"Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group","volume":"341","author":"Rubins","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.vph.2005.07.012_bib123","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJM199610033351401","article-title":"The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events trial investigators","volume":"335","author":"Sacks","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.vph.2005.07.012_bib124","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.2174\/1568026043387692","article-title":"Pharmacogenetics of drug transporters and its impact on the pharmacotherapy","volume":"4","author":"Sakaeda","year":"2004","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.vph.2005.07.012_bib125","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s00109-002-0381-z","article-title":"Effects of SREBF-1a and SCAP polymorphisms on plasma levels of lipids, severity, progression and regression of coronary atherosclerosis and response to therapy with fluvastatin","volume":"80","author":"Salek","year":"2002","journal-title":"J. Mol. Med."},{"key":"10.1016\/j.vph.2005.07.012_bib126","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/0021-9150(94)90090-6","article-title":"The effects of fibrates on lipoprotein and hemostatic coronary risk factors","volume":"111","author":"Schonfeld","year":"1994","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.vph.2005.07.012_bib127","doi-asserted-by":"crossref","first-page":"263","DOI":"10.2165\/00003088-200140040-00003","article-title":"Clinical pharmacokinetics of fluvastatin","volume":"40","author":"Scripture","year":"2001","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.vph.2005.07.012_bib128","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0140-6736(03)12948-0","volume":"361","author":"Sever","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.vph.2005.07.012_bib129","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1345\/aph.10315","article-title":"Statin-fibrate combination therapy","volume":"35","author":"Shek","year":"2001","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.vph.2005.07.012_bib130","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1056\/NEJM198005293022202","article-title":"Cholestyramine promotes receptor-mediated low-density-lipoprotein catabolism","volume":"302","author":"Shepherd","year":"1980","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.vph.2005.07.012_bib131","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJM199511163332001","article-title":"Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group","volume":"333","author":"Shepherd","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.vph.2005.07.012_bib132","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/S0140-6736(02)11600-X","article-title":"Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial","volume":"360","author":"Shepherd","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.vph.2005.07.012_bib133","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1517\/14622416.5.7.779","article-title":"Pharmacogenomics and drug response in cardiovascular disorders","volume":"5","author":"Siest","year":"2004","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.vph.2005.07.012_bib134","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/00005344-200208000-00001","article-title":"Muscular side effects of statins","volume":"40","author":"Sinzinger","year":"2002","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.vph.2005.07.012_bib135","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s11883-001-0005-z","article-title":"New statins and new doses of older statins","volume":"3","author":"Stein","year":"2001","journal-title":"Curr. Atheroscler. Rep."},{"key":"10.1016\/j.vph.2005.07.012_bib136","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1093\/ajhp\/59.10.932","article-title":"Colesevelam hydrochloride","volume":"59","author":"Steinmetz","year":"2002","journal-title":"Am. J. Health-Syst. Pharm."},{"key":"10.1016\/j.vph.2005.07.012_bib137","first-page":"306","article-title":"Combination therapy for the treatment of dyslipidemia","volume":"5","author":"Streja","year":"2004","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"10.1016\/j.vph.2005.07.012_bib138","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1161\/01.CIR.0000034044.95911.DC","article-title":"Inhibition of intestinal cholesterol absorption by ezetimibe in humans","volume":"106","author":"Sudhop","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.vph.2005.07.012_bib139","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0168-8227(03)00163-3","article-title":"Leptin receptor polymorphism is associated with serum lipid levels and impairment of cholesterol lowering effect by simvastatin in Japanese men","volume":"62","author":"Takahashi-Yasuno","year":"2003","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.vph.2005.07.012_bib140","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1001\/jama.289.13.1681","article-title":"Statin-associated myopathy","volume":"289","author":"Thompson","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.vph.2005.07.012_bib141","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/nm824","article-title":"PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect","volume":"9","author":"Tunaru","year":"2003","journal-title":"Nat. Med."},{"key":"10.1016\/j.vph.2005.07.012_bib142","doi-asserted-by":"crossref","first-page":"441","DOI":"10.2165\/00002018-200022060-00003","article-title":"HMG-CoA reductase inhibitors and myotoxicity","volume":"22","author":"Ucar","year":"2000","journal-title":"Drug Saf."},{"key":"10.1016\/j.vph.2005.07.012_bib143","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1038\/sj.bjp.0703235","article-title":"Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663","volume":"129","author":"van Heek","year":"2000","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.vph.2005.07.012_bib144","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.2337\/diacare.26.4.1216","article-title":"Common cholesteryl ester transfer protein gene polymorphisms and the effect of atorvastatin therapy in type 2 diabetes","volume":"26","author":"van Venrooij","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.vph.2005.07.012_bib145","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/S0140-6736(89)91108-2","article-title":"Lovastatin, isoprenes, and myopathy","volume":"2","author":"Walravens","year":"1989","journal-title":"Lancet"},{"key":"10.1016\/j.vph.2005.07.012_bib146","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1053\/euhj.2000.2313","article-title":"Statin therapy is associated with reduced restenosis rates after coronary stent implantation in carriers of the Pl(A2)allele of the platelet glycoprotein IIIa gene","volume":"22","author":"Walter","year":"2001","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.vph.2005.07.012_bib147","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1172\/JCI1343","article-title":"Linkage between cholesterol 7alpha-hydroxylase and high plasma low-density lipoprotein cholesterol concentrations","volume":"101","author":"Wang","year":"1998","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.vph.2005.07.012_bib148","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1124\/dmd.30.12.1352","article-title":"Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes","volume":"30","author":"Wang","year":"2002","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.vph.2005.07.012_bib149","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S0021-9150(03)00296-X","article-title":"Efficacy of fenofibrate and simvastatin on endothelial function and inflammatory markers in patients with combined hyperlipidemia: relations with baseline lipid profiles","volume":"170","author":"Wang","year":"2003","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.vph.2005.07.012_bib150","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/sj.tpj.6500195","article-title":"Haplotypes of the cholesteryl ester transfer protein gene predict lipid-modifying response to statin therapy","volume":"3","author":"Winkelmann","year":"2003","journal-title":"Pharmacogenomics J."},{"key":"10.1016\/j.vph.2005.07.012_bib151","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1161\/01.CIR.103.6.792","article-title":"Common hepatic lipase gene promoter variant determines clinical response to intensive lipid-lowering treatment","volume":"103","author":"Zambon","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.vph.2005.07.012_bib152","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/humu.20121","article-title":"Variations in human HM74 (GPR109B) and HM74A (GPR109A) niacin receptors","volume":"25","author":"Zellner","year":"2005","journal-title":"Human Mutat."},{"key":"10.1016\/j.vph.2005.07.012_bib153","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1146\/annurev.bi.65.070196.001325","article-title":"Protein prenylation: molecular mechanisms and functional consequences","volume":"65","author":"Zhang","year":"1996","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.vph.2005.07.012_bib154","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0021-9150(02)00196-X","article-title":"Association of the factor XII 46C>T polymorphism with risk of coronary heart disease (CHD) in the WOSCOPS study","volume":"165","author":"Zito","year":"2002","journal-title":"Atherosclerosis"}],"container-title":["Vascular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189105002132?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189105002132?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T08:40:52Z","timestamp":1736152852000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1537189105002132"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,2]]},"references-count":154,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2006,2]]}},"alternative-id":["S1537189105002132"],"URL":"https:\/\/doi.org\/10.1016\/j.vph.2005.07.012","relation":{},"ISSN":["1537-1891"],"issn-type":[{"value":"1537-1891","type":"print"}],"subject":[],"published":{"date-parts":[[2006,2]]}}}